Company / Capital Expenditures
Syndax Pharmaceuticals Inc Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$187.0K
FY2025
5-year range
$0 / $187.0K
FY2021-FY2025
Trend
-
vs FY2024
Sector context
#161 of 194
Health Care
What the data says
Syndax Pharmaceuticals Inc's capital expenditures of $187,000 is lower than 83% of companies in the Health Care sector (FY2025). Capital Expenditures has fluctuated over the past 10 years, ranging from $0 in FY2024 to $261,000 in FY2018.
Based on SEC 10-K filings.
$187,000 in FY2025 with a 5-year CAGR of +0.0%.
Improved from $0 to $187,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +0.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 194This company $187.0K Sector average $117.5M
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.0%, indicating consistent growth.
- Ranks #161 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2018.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $187.0K | - |
| FY2024 | $0 | - |
| FY2023 | $0 | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $129.0K | -31.0% |
| FY2020 | $187.0K | +122.6% |
| FY2019 | $84.0K | -67.8% |
| FY2018 | $261.0K | +432.7% |
| FY2017 | $49.0K | +1125.0% |
| FY2016 | $4.0K | -91.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026